Hostname: page-component-78c5997874-j824f Total loading time: 0 Render date: 2024-11-05T08:40:32.628Z Has data issue: false hasContentIssue false
  • English
  • Français

Do Results of Surveillance Cultures Impact the Choice of Empirical Antibiotics Among Patients with Carbapenem-Resistant Acinetobacter baumannii Infections?

Published online by Cambridge University Press:  10 September 2015

Rossana Rosa ,
Jose Castro ,
Rachel Latibeaudiere ,
Nicholas Namias  and
L. Silvia Munoz-Price
Rossana Rosa
Affiliation:
Department of Medicine, Jackson Memorial Hospital, Miami, Florida
Jose Castro
Affiliation:
Division of Infectious Diseases, University of Miami Miller School of Medicine, Miami, Florida
Rachel Latibeaudiere
Affiliation:
Department of Medicine, Jackson Memorial Hospital, Miami, Florida
Nicholas Namias
Affiliation:
Department of Surgery, University of Miami Miller School of Medicine, Miami, Florida
L. Silvia Munoz-Price*
Affiliation:
Institute for Health and Society and Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin
*
Address correspondence to L. Silvia Munoz-Price, Institute for Health and Society and Department of Medicine, Froedtert and the Medical College of Wisconsin Health Research Center, P.O. Box 26509, Milwaukee WI 53226 ([email protected]).
Get access Rights & Permissions [Opens in a new window]

Abstract

We aimed to determine whether the results of surveillance cultures were associated with use of appropriate empirical antibiotic therapy among patients with carbapenem-resistant Acinetobacter baumannii infections. We found that surveillance status was not associated with appropriate empirical antibiotic therapy (P=.36). There were significant delays to concordant therapy among surveillance-positive patients (P=.03).

Infect. Control Hosp. Epidemiol. 2015;36(12):1455–1457

Type
Concise Communications
Information
Infection Control & Hospital Epidemiology , Volume 36 , Issue 12 , December 2015 , pp. 1455 - 1457
Copyright
© 2015 by The Society for Healthcare Epidemiology of America. All rights reserved 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

REFERENCES

1. Munoz-Price, LS, Weinstein, RA. Acinetobacter infection. N Engl J Med 2008;358:1271–1281.CrossRefGoogle ScholarPubMed
2. Chopra, T, Marchaim, D, Awali, RA, et al. Epidemiology of bloodstream infections caused by Acinetobacter baumannii and impact of drug resistance to both carbapenems and ampicillin-sulbactam on clinical outcomes. Antimicrob Agents Chemother 2013;57:6270–6275.CrossRefGoogle ScholarPubMed
3. Lee, HY, Chen, CL, Wu, SR, Huang, CW, Chiu, CH. Risk factors and outcome analysis of Acinetobacter baumannii complex bacteremia in critical patients. Crit Care Med 2014;42:1081–1088.CrossRefGoogle ScholarPubMed
4. Latibeaudiere, R, Rosa, R, Laowansiri, P, Arheart, K, Namias, N, Munoz-Price, LS. Surveillance cultures growing carbapenem-resistant Acinetobacter baumannii predict the development of clinical infections: a retrospective cohort study. Clin infect Dis 2015;60:415–422.CrossRefGoogle ScholarPubMed
5. Munoz-Price, LS, Namias, N, Cleary, T, et al. Acinetobacter baumannii: association between environmental contamination of patient rooms and occupant status. Infect Control Hosp Epidemiol 2013;34:517–520.CrossRefGoogle ScholarPubMed
6. Horan, TC, Andrus, M, Dudeck, MA. CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. Am J Infect Control 2008;36:309–332.CrossRefGoogle ScholarPubMed
7. Centers for Diseases Control and Prevention. Antibiotic resistance threats in the United States, 2013. http://www.cdc.gov/drugresistance/threat-report-2013/. Published 2013. Accessed February 2, 2014.Google Scholar
8. Shlaes, DM, Sahm, D, Opiela, C, Spellberg, B. The FDA reboot of antibiotic development. Antimicrob Agents Chemother 2013;57:4605–4607.CrossRefGoogle ScholarPubMed
9. Spellberg, B, Bonomo, RA. The deadly impact of extreme drug resistance in Acinetobacter baumannii . Crit Care Med 2014;42:1289–1291.CrossRefGoogle ScholarPubMed
10. Rosa, R, Arheart, KL, Depascale, D, et al. environmental exposure to carbapenem-resistant Acinetobacter baumannii as a risk factor for patient acquisition of A. baumannii . Infect Control Hosp Epidemiol 2014;35:430–433.CrossRefGoogle ScholarPubMed